Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 6/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | CA12 | O43570 | 2/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.95 |
| ▸ | CA2 | P00918 | 2/20 | 0.95 |
| ▸ | CA7 | P43166 | 2/20 | 0.95 |
| ▸ | CA9 | Q16790 | 2/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.95 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.95 |
| ▸ | CA4 | P22748 | 1/20 | 0.95 |
| ▸ | CA6 | P23280 | 1/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL17913110 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL27171063 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28160750 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL17156443 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8433746 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29360246 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29606432 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29362663 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1509155 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1967 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736087-B | Preparation method of triammonium rhodotricarboxylic acid | 天津市科密欧化学试剂有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117736087-A | Preparation method of triammonium rhodotricarboxylic acid | 天津市科密欧化学试剂有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-10239918-B2 | Cahuitamycins and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180162906-A1 | CAHUITAMYCINS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-06-14 | — | — | US | disclosed |
| EP-3313182-A1 | CAHUITAMYCINS AND METHODS OF MAKING AND USING THE SAME | The Regents of The University of Michigan (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016191514-A1 | CAHUITAMYCINS AND METHODS OF MAKING AND USING THE SAME | THE REGNETS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-01 | — | — | WO | disclosed |
| US-5034370-A | Reaction product of a salicylic acid derivative with formaldehyde and an aromatic compound | SUMITOMO DUREZ COMPANY, LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162906-A1 | CAHUITAMYCINS AND METHODS OF MAKING AND USING THE SAME | NRDC, NISCH, GANAB | ALDH1A1 2759/4885KDM4E 2777/4885HPGD 114/4885 |
| US-10239918-B2 | Cahuitamycins and methods of making and using the same | NRDC, NISCH, GANAB | ALDH1A1 2759/4885KDM4E 2777/4885HPGD 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.